PDE inhibitors: A new approach to treat metabolic syndrome?

Current Opinion in Pharmacology

Volumn 11, Issue 6, 2011, Pages 698-706

  Lugnier, Claire ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CILOSTAZOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NITRIC OXIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 3B; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE IX; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VI; PHOSPHODIESTERASE VII; PHOSPHODIESTERASE VIII; PHOSPHODIESTERASE X; PHOSPHODIESTERASE XI; SPLEEN EXONUCLEASE; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZAPRINAST;

ADIPOCYTE; ARTICLE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 82255192398     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2011.09.012     Document Type: Review

References (97)

1. Y. Matsuzawa, T. Funahashi, and T. Nakamura The concept of metabolic syndrome; contribution of visceral fat accumulation and its molecular mechanism J Atheroscler Thromb 2011 10.5551/jat.7922
2. E. Kassi, P. Pervanidou, G. Kaltsas, and G. Chrousos Metabolic syndrome: definitions and controversies BMC Med 2011 10.1186/1741-7015-9-48
3. C. Lugnier Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents Pharmacol Ther 109 2006 366 398 (Pubitemid 43132818)
4. S.H. Francis, M.A. Blount, and J.D. Corbin Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions Physiol Rev 91 2011 651 690
5. C. Lugnier, A. Follénius, D. Gérard, and J.C. Stoclet Bepridil and flunarizine as calmodulin inhibitors Eur J Pharmacol 98 1984 157 158 (Pubitemid 14192556)
6. R.L. Gonalves, C. Lugnier, T. Keravis, M.J. Lopes, F.A. Fantini, M. Schmitt, S.F. Cortes, and V.S. Lemos The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue Eur J Pharmacol 620 2009 78 83
7. 2+/ calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival Circ Res 98 2006 777 784
8. F. Vandeput, S.L. Wolda, J. Krall, R. Hambleton, L. Uher, K.N. McCaw, P.B. Radwanski, V. Florio, and M.A. Movsesian Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes J Biol Chem 282 2007 32749 32757 (Pubitemid 350159317)
9. C.C. Heikaus, J. Pandit, and R.E. Klevit Cyclic nucleotide binding GAF domains from phosphodiesterases: structural and mechanistic insights Structure 17 2009 1551 1557
10. T. Podzuweit, P. Nennstiel, and A. Müller Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine Cell Signal 7 1995 733 738
11. F.G. Boess, M. Hendrix, F.J. van der Staay, C. Erb, R. Schreiber, W. van Staveren, J. de Vente, J. Prickaerts, A. Blokland, and G. Koenig Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity, and memory performance Neuropharmacol 47 2004 1081 1092 (Pubitemid 39535847)
12. P.B. Snyder, J.M. Esselstyn, K. Loughney, S.L. Wolda, and V.A. Florio The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis J Lipid Res 46 2005 494 503 (Pubitemid 43109786)
13. R.J. Chambers, K. Abrams, N.Y. Garceau, A.V. Kamath, C.M. Manley, S.C. Lilley, D.A. Otte, D.O. Scott, A.L. Sheils, and D.A. Tess A new chemical tool for exploring the physiological function of the PDE2 isozyme Bioorg Med Chem Lett 16 2006 307 310 (Pubitemid 41680619)
14. J. Seybold, D. Thomas, M. Witzenrath, S. Boral, A.C. Hocke, A. Bürger, A. Hatzelmann, H. Tenor, C. Schudt, and M. Krüll Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability Blood 105 2005 3569 3576 (Pubitemid 40628202)
15. A. Masood, Y. Huang, H. Hajjhussein, L. Xiao, H. Li, W. Wang, A. Hamza, C.G. Zhan, and J.M. O'Donnell Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling J Pharmacol Exp Ther 331 2009 690 699
16. H. Hidaka, H. Hayashi, H. Kohri, Y. Kimura, T. Hosokawa, T. Igawa, and Y. Saitoh Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation J Pharmacol Exp Ther 211 1979 26 30 (Pubitemid 10201537)
17. M. Ito, T. Tanaka, M. Saitoh, H. Masuoka, T. Nakano, and H. Hidaka Selective inhibition of cyclic AMP phosphodiesterase from various human tissues by milrinone, a potent cardiac bipyridine Biochem Pharmacol 37 1988 2041 2044
18. K.J. Murray, P.J. England, T.J. Hallam, J. Maguire, K. Moores, M.L. Reeves, A.W. Simpson, and T.J. Rink The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function Br J Pharmacol 99 1990 612 616 (Pubitemid 20069173)
19. N. Komas, C. Lugnier, A. Le Bec, C. Serradeil-Le Gal, G. Barthélémy, and J.C. Stoclet Differential sensitivity to cardiotonic drugs of cyclic AMP phosphodiesterases isolated from canine ventricular and sinoatrial-enriched tissues J Cardiovasc Pharmacol 14 1989 213 220 (Pubitemid 19189500)
20. Y. Liu, Y. Shakur, M. Yoshitake, and J. Ji Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake Cardiovasc Drug Rev 19 2001 369 386 (Pubitemid 34260705)
21. C. Lugnier, P. Schoeffter, A. Le Bec, E. Strouthou, and J.C. Stoclet Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta Biochem Pharmacol 35 1986 1743 1751 (Pubitemid 16067796)
22. M.D. Houslay, P. Schafer, and K.Y. Zhang Keynote review: phosphodiesterase-4 as a therapeutic target Drug Discov Today 10 2005 1503 1519 (Pubitemid 41527193)
23. S.G. Dastidar, D. Rajagopal, and A. Ray Therapeutic benefit of PDE4 inhibitors in inflammatory diseases Curr Opin Investig Drugs 8 2007 364 372 (Pubitemid 46700993)
24. A. Hatzelmann, E.J. Morcillo, G. Lungarella, S. Adnot, S. Sanjar, R. Beume, C. Schudt, and H. Tenor The preclinical pharmacology of roflumilast - a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease Pulm Pharmacol Ther 23 2010 235 256
25. E. Boichot, J.L. Wallace, N. Germain, M. Corbel, C. Lugnier, V. Lagente, and J.J. Bourguignon Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine J Pharmacol Exp Ther 292 2000 647 653 (Pubitemid 30067428)
26. H. Coste, and P. Grondin Characterization of a novel potent and specific inhibitor of type V phosphodiesterase Biochem Pharmacol 50 1995 1577 1585
27. S.H. Francis, J.D. Corbin, and E. Bischoff Cyclic GMP-hydrolyzing phosphodiesterases Handb Exp Pharmacol 191 2009 367 408
28. E.D. Michelakis, W. Tymchak, M. Noga, L. Webster, X.C. Wu, D. Lien, S.H. Wang, D. Modry, and S.L. Archer Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension Circulation 108 2003 2066 2069 (Pubitemid 37337580)
29. R. Lee, S. Wolda, E. Moon, J. Esselstyn, C. Hertel, and A. Lerner PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP Cell Signal 14 2002 277 284 (Pubitemid 34102457)
30. S.J. Smith, L.B. Cieslinski, R. Newton, L.E. Donnelly, P.S. Fenwick, A.G. Nicholson, P.J. Barnes, M.S. Barnette, and M.A. Giembycz Discovery of BRL 50481 [3-(N, N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes Mol Pharmacol 66 2004 1679 1689 (Pubitemid 39564796)
31. K. Kadoshima-Yamaoka, M. Murakawa, M. Goto, Y. Tanaka, H. Inoue, H. Murafuji, A. Nagahira, Y. Hayashi, K. Nagahira, and K. Miura ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced IFN-gamma production by mouse activated T lymphocytes Immunol Lett 122 2009 193 197
32. A.G. Vang, S.Z. Ben-Sasson, H. Dong, B. Kream, M.P. DeNinno, M.M. Claffey, W. Housley, R.B. Clark, P.M. Epstein, and S. Brocke PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER PLoS ONE 2010 10.1371/journal.pone.0012011
33. F. Wunder, A. Tersteegen, A. Rebmann, C. Erb, T. Fahrig, and M. Hendrix Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line Mol Pharmacol 68 2005 1775 1781 (Pubitemid 41654360)
34. P.H. Hutson, E.N. Finger, B.C. Magliaro, S.M. Smith, A. Converso, P.E. Sanderson, D. Mullins, L.A. Hyde, B.K. Eschle, and Z. Turnbull The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1, 5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents Neuropharmacology 61 2011 665 676
35. J.A. Siuciak, D.S. Chapin, J.F. Harms, L.A. Lebel, S.A. McCarthy, L. Chambers, A. Shrikhande, S. Wong, F.S. Menniti, and C.J. Schmidt Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis Neuropharmacology 51 2006 386 396 (Pubitemid 44061894)
36. C.J. Schmidt, D.S. Chapin, J. Cianfrogna, M.L. Corman, M. Hajos, J.F. Harms, W.E. Hoffman, L.A. Lebel, S.A. McCarthy, and F.R. Nelson Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia J Pharmacol Exp Ther 325 2008 681 690 (Pubitemid 351574819)
37. S.M. Grauer, V.L. Pulito, R.L. Navarra, M.P. Kelly, C. Kelley, R. Graf, B. Langen, S. Logue, J. Brennan, and L. Jiang Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia J Pharmacol Exp Ther 331 2009 574 590
38. Kishida K, Funahashi T, Matsuzawa Y: Visceral adiposity as a target for the management of the metabolic syndrome. Ann Med 2011, doi:10.3109/07853890. 2011.564202.
39. H. Xu, G.T. Barnes, Q. Yang, G. Tan, D. Yang, C.J. Chou, J. Sole, A. Nichols, J.S. Ross, L.A. Tartaglia, and H. Chen Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance J Clin Invest 112 2003 1821 1830 (Pubitemid 38063705)
40. R. Monteiro, and I. Azevedo Chronic inflammation in obesity and the metabolic syndrome Mediators Inflamm 2010 10.1155/2010/289645
41. E. Degerman, and V. Manganiello Phosphodiesterase 3B: an important regulator of energy homeostasis J.A. Beavo, S.H. Francis, M.D. Houslay, Cyclic Nucleotide Phosphodiesterases in Health and Disease 2006 CRC Press Boca Raton 79 97
42. H. Walz, L. Härndahl, N. Wierup, E. Zmuda-Trzebiatowska, F. Svennelid, V. Manganiello, T. Ploug, F. Sundler, E. Degerman, B. Ahrén, and L. Holst Early and rapid development of insulin resistance, islet dysfunction, and glucose intolerance after high-fat feeding in mice overexpressing phosphodiesterase 3B J Endocrinol 189 2006 629 641
43. Y. Tang, H. Osawa, H. Onuma, T. Nishimiya, M. Ochi, A. Sugita, and H. Makino Phosphodiesterase 3B gene expression is enhanced in the liver but reduced in the adipose tissue of obese insulin resistant db/db mouse Diabetes Res Clin Pract 54 2001 145 155 (Pubitemid 33016321)
44. T. Rahn Landström, J. Mei, M. Karlsson, V. Manganiello, and E. Degerman Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumour necrosis factor alpha and cAMP Biochem J 346 2000 337 343 (Pubitemid 30148118)
45. H.H. Zhang, M. Halbleib, F. Ahmad, V.C. Manganiello, and A.S. Greenberg Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP Diabetes 51 2002 2929 2935
46. R. Zhang, E. Maratos-Flier, and J.S. Flier Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B Endocrinology 150 2009 3076 3082
47. C. Moro, E. Klimcakova, M. Lafontan, M. Berlan, and J. Galitzky Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis Br J Pharmacol 152 2007 1102 1110 (Pubitemid 350166053)
48. A. Aversa, M. Caprio, A. Antelmi, A. Armani, M. Brama, E.A. Greco, D. Francomano, M. Calanchini, G. Spera, and L. Di Luigi Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro J Sex Med 8 2011 696 704 10.1111/j.1743-6109.2010.02152.x
49. B. Furman, W.K. Ong, and N.J. Pyne Cyclic AMP signaling in pancreatic islets Adv Exp Med Biol 654 2010 281 304
50. E. Heimann, H.A. Jones, S. Resjö, V.C. Manganiello, L. Stenson, and E. Degerman Expression and regulation of cyclic nucleotide phosphodiesterases in human and rat pancreatic islets PLoS ONE 2010 10.1371/journal.pone.0014191
51. A. Zhao, H. Zhao, J. Teague, W. Fujimoto, and J. Beavo Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B Proc Natl Acad Sci USA 94 1997 3223 3228 (Pubitemid 27157292)
52. A. Zhao, K. Bornfeldt, and J. Beavo Leptin inhibits insulin secretion by activation of phosphodiesterase 3B J Clin Invest 102 1998 869 873 (Pubitemid 28419231)
53. L. Härndahl, X. Jing, R. Ivarsson, E. Degerman, B. Ahrén, V. Manganiello, E. Renström, and L. Holst Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulin J Biol Chem 277 2002 37446 37455
54. L. Härndahl, N. Wierup, S. Enerbäck, H. Mulder, V. Manganiello, F. Sundler, E. Degerman, B. Ahrén, and L. Holst Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology J Biol Chem 279 2004 15214 15222 (Pubitemid 38618917)
55. J.C. Parker, M.A. VanVolkenburg, R.J. Ketchum, K.L. Brayman, and K.M. Andrews Cyclic AMP phosphodiesterases of human and rat islets of Langerhans: contributions of types III and IV to the modulation of insulin secretion Biochem Biophys Res Commun 217 1995 916 923 (Pubitemid 26019742)
56. P. Han, J. Werber, M. Surana, N. Fleischer, and T. Michaeli The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion J Biol Chem 274 1999 22337 22344
57. D. Waddleton, W. Wu, Y. Feng, C. Thompson, M. Wu, Y.P. Zhou, A. Howard, N. Thornberry, J. Li, and J.A. Mancini Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832/13) cells and rat islets Biochem Pharmacol 76 2008 884 893
58. B. Furman, N. Pyne, P. Flatt, and F. O'Harte Targeting beta-cell cyclic 3′5′ adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus J Pharm Pharmacol 56 2004 1477 1492 (Pubitemid 39610499)
59. T. Keravis, and C. Lugnier Cyclic nucleotide phosphodiesterase (PDE) superfamily and smooth muscle signaling J.P. Savineau, New Frontiers in Smooth Muscle Biology and Physiology 2007 Transworld Research Network 269 289
60. N. Komas, C. Lugnier, and J.C. Stoclet Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors Br J Pharmacol 104 1991 495 503
61. D. Kim, S.D. Rybalkin, X. Pi, Y. Wang, C. Zhang, T. Munzel, J.A. Beavo, B.C. Berk, and C. Yan Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance Circulation 104 2001 2338 2343 (Pubitemid 33049518)
62. A. Virdis, E. Duranti, and S. Taddei Oxidative stress and vascular damage in hypertension: role of angiotensin II Int J Hypertens 2011 10.4061/2011/916310
63. F.R. Giachini, V.V. Lima, F.S. Carneiro, R.C. Tostes, and R.C. Webb Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1 Hypertension 57 2011 655 663
64. D. Kim, T. Aizawa, H. Wei, X. Pi, S.D. Rybalkin, B.C. Berk, and C. Yan Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling J Mol Cell Cardiol 38 2005 175 184 (Pubitemid 40038664)
65. T. Matsumoto, T. Kobayashi, and K. Kamata Alterations in EDHF-type relaxation and phosphodiesterase activity in mesenteric arteries from diabetic rats Am J Physiol Heart Circ Physiol 285 2003 H283 H291
66. N. Begum, S. Hockman, and V.C. Manganiello Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins J Biol Chem 286 2011 26238 26249
67. T. Keravis, N. Komas, and C. Lugnier Cyclic nucleotide hydrolysis in bovine aortic endothelial cells in culture: differential regulation in cobblestone and spindle phenotypes J Vasc Res 37 2000 235 249
68. L. Favot, T. Keravis, and C. Lugnier Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4 Thromb Haemost 92 2004 634 645 (Pubitemid 39248022)
69. T. Keravis, A.P. Silva, L. Favot, and C. Lugnier Role of PDEs in vascular health and disease: endothelial PDEs and angiogenesis J.A. Beavo, S.H. Francis, M.D. Houslay, Cyclic Nucleotide Phosphodiesterases in Health and Disease 2006 CRC Press Boca Raton 417 439
70. D.H. Maurice, and D.G. Tilley Regulation of PDE expression in arteries: role in controlling vascular cyclic nucleotide signaling J.A. Beavo, S.H. Francis, M.D. Houslay, Cyclic Nucleotide Phosphodiesterases in Health and Disease 2006 CRC Press Boca Raton 441 463
71. T. Kessler, and C. Lugnier Rolipram increases Cyclic GMP content in L-Arginine-treated cultured bovine aortic endothelial cells Eur J Pharmacol 290 1995 163 167
72. H. Ota, M. Eto, M.R. Kano, S. Ogawa, K. Iijima, M. Akishita, and Y. Ouchi Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells Arterioscler Thromb Vasc Biol 28 2008 1634 1639
73. H.S. Elbatarny, S.J. Netherton, J.D. Ovens, A.V. Ferguson, and D.H. Maurice Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases Eur J Pharmacol 558 2007 7 13 (Pubitemid 46328874)
74. (2+) responses in endothelial cells Br J Pharmacol 154 2008 82 92 (Pubitemid 351620395)
75. W.T. Wong, X.Y. Tian, A. Xu, J. Yu, C.W. Lau, R.L. Hoo, Y. Wang, V.W. Lee, K.S. Lam, P.M. Vanhoutte, and Y. Huang Adiponectin is required for PPARγ-mediated improvement of endothelial function in diabetic mice Cell Metab 14 2011 104 115
76. T. Keravis, G. Vandecasteele, W. Mokni, R. Fischmeister, and C. Lugnier Identification of PDE1 and PDE5 in adult rat left ventricle cardiomyocytes J Mol Cell Cardiol 42 2007 S49 S50
77. B. Muller, C. Lugnier, and J.C. Stoclet Implication of cyclic AMP in the positive inotropic effects of cyclic GMP-inhibited cyclic AMP phosphodiesterase inhibitors on guinea pig isolated left atria J Cardiovasc Pharmacol 15 1990 444 451 (Pubitemid 20063746)
78. W. Mokni, T. Keravis, N. Etienne-Selloum, A. Walter, M.O. Kane, V.B. Schini-Kerth, and C. Lugnier Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II PLoS ONE 5 2010 e14227 10.1371/journal.pone
79. 2+/calmodulin- stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy Circ Res 105 2009 956 964
80. M. Zhang, N. Koitabashi, T. Nagayama, R. Rambaran, N. Feng, E. Takimoto, T. Koenke, B. O'Rourke, H.C. Champion, M.T. Crow, and D.A. Kass Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes Cell Signal 20 2008 2231 2236
81. E. Takimoto, H.C. Champion, M. Li, D. Belardi, S. Ren, E.R. Rodriguez, D. Bedja, K.L. Gabrielson, Y. Wang, and D.A. Kass Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy Nat Med 11 2005 214 222 (Pubitemid 40321358)
82. Z. Lu, X. Xu, X. Hu, S. Lee, J.H. Traverse, G. Zhu, J. Fassett, Y. Tao, P. Zhang, and C. dos Remedios Oxidative stress regulates left ventricular PDE5 expression in the failing heart Circulation 2010 10.1161/CIRCULATIONAHA.109. 906818
83. T. Radovits, T. Bömicke, G. Kökény, R. Arif, S. Loganathan, K. Kécsán, S. Korkmaz, E. Barnucz, P. Sandner, M. Karck, and G. Szabó The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus Br J Pharmacol 156 2009 909 919
84. A. Abi-Gerges, W. Richter, F. Lefebvre, P. Mateo, A. Varin, C. Heymes, J.L. Samuel, C. Lugnier, M. Conti, R. Fischmeister, and G. Vandecasteele Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals Circ Res 105 2009 784 792
85. E. Caglayan, F. Blaschke, Y. Takata, and W.A. Hsueh Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways Curr Opin Pharmacol 5 2005 135 142 (Pubitemid 40378743)
86. V. Mor, and M.K. Unnikrishnan 5′-adenosine monophosphate-activated protein kinase and the metabolic syndrome Endocr Metab Immune Disord Drug Targets 11 2011 206 216
87. A. Salminen, J.M.T. Hyttinen, and K. Kaarniranta AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan J Mol Med 2011 10.1007/s00109-011-0748-0
88. B. Viollet, L. Lantier, J. Devin-Leclerc, S. Hébrard, C. Amouyal, R. Mounier, M. Foretz, and F. Andreelli Targeting the AMPK pathway for the treatment of Type 2 diabetes Front Biosci 14 2009 3380 3400
89. Zaccolo M: Spatial control of cyclic nucleotide signaling in health and disease. Curr Opin Pharmacol 2011.
90. T. Yamauchi, J. Kamon, Y. Ito, A. Tsuchida, T. Yokomizo, S. Kita, T. Sugiyama, M. Miyagishi, K. Hara, and M. Tsunoda Cloning of adiponectin receptors that mediate antidiabetic metabolic effects Nature 423 2003 762 769 (Pubitemid 36735700)
91. X.K. Mahadev, L. Fuchsel, R. Ouedraogo, S.Q. Xu, and B.J. Goldstein Adiponectin suppresses IkappaB kinase activation induced by tumor necrosis factor-alpha or high glucose in endothelial cells: role of cAMP and AMP kinase signaling Am J Physiol Endocrinol Metab 293 2007 E1836 E1844
92. I. Yougbare, C.S. Morin, F.Y. Senouvo, C. Sirois, R. Albadine, C. Lugnier, and E. Rousseau NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues Am J Physiol Lung Cell Mol Physiol 301 2011 441 450
93. S.Y. Park, H.K. Shin, J.H. Lee, C.D. Kim, W.S. Lee, B.Y. Rhim, and K.W. Hong Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription J Pharmacol Exp Ther 329 2009 571 579
94. F. Saad, and L.J. Gooren The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2 J Obes 2011 10.1155/2011/471584
95. L. Di Luigi, C. Baldari, P. Sgr, G.P. Emerenziani, M.C. Gallotta, S. Bianchini, F. Romanelli, F. Pigozzi, A. Lenzi, and L. Guidetti The type 5 phosphodiesterase inhibitor tadalafil influences salivary cortisol, testosterone, and dehydroepiandrosterone sulphate responses to maximal exercise in healthy men J Clin Endocrinol Metab 93 2008 3510 3514
96. S.A. Andric, M.M. Janjic, N.J. Stojkov, and T.S. Kostic Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway Am J Physiol Endocrinol Metab 299 2010 E544 E550
97. K.L. Saraiva, A.K. Silva, M.I. Wanderley, A.A. De Araújo, J.R. De Souza, and C.A. Peixoto Chronic treatment with sildenafil stimulates Leydig cell and testosterone secretion Int J Exp Pathol 90 2009 454 462